JP2023519101A5 - - Google Patents

Info

Publication number
JP2023519101A5
JP2023519101A5 JP2022548612A JP2022548612A JP2023519101A5 JP 2023519101 A5 JP2023519101 A5 JP 2023519101A5 JP 2022548612 A JP2022548612 A JP 2022548612A JP 2022548612 A JP2022548612 A JP 2022548612A JP 2023519101 A5 JP2023519101 A5 JP 2023519101A5
Authority
JP
Japan
Prior art keywords
grna
nucleic acid
sequence
exon
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519101A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/017942 external-priority patent/WO2021163550A1/en
Publication of JP2023519101A publication Critical patent/JP2023519101A/ja
Publication of JP2023519101A5 publication Critical patent/JP2023519101A5/ja
Pending legal-status Critical Current

Links

JP2022548612A 2020-02-12 2021-02-12 Rp1関連網膜変性症のハプロタイプに基づく処置 Pending JP2023519101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062975636P 2020-02-12 2020-02-12
US62/975,636 2020-02-12
PCT/US2021/017942 WO2021163550A1 (en) 2020-02-12 2021-02-12 Haplotype-based treatment of rp1 associated retinal degenerations

Publications (2)

Publication Number Publication Date
JP2023519101A JP2023519101A (ja) 2023-05-10
JP2023519101A5 true JP2023519101A5 (cg-RX-API-DMAC7.html) 2024-02-21

Family

ID=77292955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548612A Pending JP2023519101A (ja) 2020-02-12 2021-02-12 Rp1関連網膜変性症のハプロタイプに基づく処置

Country Status (6)

Country Link
US (2) US12129496B2 (cg-RX-API-DMAC7.html)
EP (1) EP4103238A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023519101A (cg-RX-API-DMAC7.html)
CN (1) CN115427568A (cg-RX-API-DMAC7.html)
AU (1) AU2021219795A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021163550A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022216614B2 (en) 2021-02-05 2026-03-05 Christiana Care Gene Editing Institute, Inc. Methods of and compositions for reducing gene expression and/or activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
JPS57124055A (en) 1981-01-27 1982-08-02 Toyota Motor Corp Air-fuel ratio control device for engine
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
EP0452457B1 (en) 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
CN105408483A (zh) 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
HUE052676T2 (hu) 2013-10-11 2021-05-28 Massachusetts Eye & Ear Infirmary Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
WO2017040348A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Engineered crispr-cas9 nucleases
US11566263B2 (en) * 2016-08-02 2023-01-31 Editas Medicine, Inc. Compositions and methods for treating CEP290 associated disease
WO2018148246A1 (en) * 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
WO2018195545A2 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
US20210032612A1 (en) 2018-02-22 2021-02-04 Avellino Lab Usa, Inc. CRISPR/Cas9 Systems, and Methods of Use Thereof
EP3768327A4 (en) * 2018-03-23 2022-04-13 The Trustees of Columbia University in the City of New York GENE EDIT FOR AUTOSOMAL DOMINANT DISEASES
CA3094828A1 (en) * 2018-03-23 2019-09-26 Massachusetts Eye And Ear Infirmary Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome

Similar Documents

Publication Publication Date Title
US20250235556A1 (en) Gene therapy for autosomal dominant diseases
EP3322297B1 (en) Delivery methods and compositions for nuclease-mediated genome engineering
AU2014364051B2 (en) Methods and compositions for treating hemophilia
RU2650819C2 (ru) Способы и композиции для опосредованной нуклеазой направленной интеграции трансгенов
EP4186921A1 (en) Gene editing for autosomal dominant diseases
JP7012650B2 (ja) Dna結合ドメインと切断ドメインとを連結するための組成物
JP2020120690A (ja) 遺伝的状態の処置のための方法および組成物
WO2018162702A1 (en) Nuclease fusions for enhancing genome editing by homology-directed transgene integration
EP3867375A1 (en) Genome editing methods and constructs
Carvalho et al. Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology
Epstein et al. Combining engineered nucleases with adeno-associated viral vectors for therapeutic gene editing
US20210054372A1 (en) Methods of inactivating gene editing machineries
JP2025175283A (ja) Amdの処置のためのhtra1調節
US20240132881A1 (en) Differential knockout of an allele of a heterozygous bestrophin 1 gene
US20220307057A1 (en) Crispr compositions and methods for promoting gene editing of gata2
HK40075787A (en) Gene therapy for autosomal dominant diseases
US12031149B2 (en) Compositions and methods for promoting gene editing of CXCR4 gene
JP2025506403A5 (cg-RX-API-DMAC7.html)
WO2026032020A1 (zh) Aav介导的rpgr x连锁视网膜变性的基因编辑治疗方法
WO2026036033A1 (en) Products and methods for treatment of autosomal dominant genetic diseases involving diversified disease causing mutations
HK40069063B (en) Methods and compositions for treating thalassemia or sickle cell disease
WO2026088097A1 (en) Mutation-independent genome editing
HK1251615B (en) Gene therapy for autosomal dominant diseases
US20230173107A1 (en) Guide rna that targets a mutant human inosine monophosphate deydrogenase i allele